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Renal cell carcinoma (RCC) of the clear cell type is the most
common malignant tumour of the kidney and has a very poor
prognosis. Approximately one-third of the patients with RCC
develop metastasis and systemic treatment using chemotherapy
and/or cytokines proved to be rather ineffective (Mulders et al,
1997). Cytogenetic and molecular investigations of sporadic RCC
revealed frequent chromosome 3p deletions and additional loss of
heterozygosity on chromosomes 5, 11 and 17 (Kovacs et al, 1988;
Anglard et al, 1991; Morita et al, 1991; Druck et al, 1995).
Although these studies led to the identification of different genes,
which are thought to be involved in carcinogenesis of RCC, the
molecular mechanisms regulating aggressive properties of RCCs,
such as invasion and metastasis, are still poorly understood.
Protein kinase C (PKC) reconstitutes a family of at least 11
related isoenzymes, which plays a major role in intracellular signal
transduction and is thought be involved in cancer biology (Blobe
et al, 1994; Stabel et al, 1994; Liu et al, 1996). According to their
structural and biochemical characteristics, PKC-isoenzymes can
be subdivided into three major groups: the conventional or clas-
sical PKC-isoenzymes (a, bI, bII, g), the novel PKC-isoenzymes
(d, e, h(L), q, m), and the atypical PKC-isoenzymes (z, i(l)). In
general the biological effects of PKC seem to be tumour- or even
cell line-specific rather than unique. Thus, PKC is thought to act as
an oncogene in breast cancer, whereas in colon cancer it was
suggested to act as an anti-oncogene (Blobe et al, 1994). These
differences may at least in part be explained by the fact that
different tissues exhibit different expression patterns of PKC-
isoenzymes, and that the subcellular distribution of a particular
PKC-isoenzyme varies depending on the cell type and conditions
analysed (Blobe et al, 1994; Jaken, 1996). Moreover, it was shown
by transfection experiments that overexpression of the same PKC-
isoenzyme may result in opposite cell biological effects,
depending on the cell line used (Borner et al, 1995; Goldstein et al,
1995). Although the expression of PKC-isoenzymes has been
investigated in different rodent and murine tissue types and some
cell lines of diverse species (Wetsel et al, 1992; Bareggi et al,
1995), little is known about the differential expression in human
tumours and specific functional implications of each isoenzyme in
tumour cell behaviour. The fact that PKC-isoenzymes differ, e.g.
in organ-specific expression patterns, subcellular distribution upon
overexpression in fibroblasts, substrate specificity and oncogenic
potential, suggests specific biological roles for each PKC-
isoenzyme. However, these roles appear to be at least partly cell
type-specific (Jaken, 1996).
Studies on primary renal proximal tubule epithelial cells
(RPTE), from which RCCs of the clear cell type are histogeneti-
cally derived, suggest that PKC might play a regulatory role for
the biological properties of RCCs. In these studies primary RPTE
as well as E1A-immortalized and SV40-transformed RPTE of 
the rat were compared for the expression and distribution of PKC-
isoenzymes (Dong et al, 1994). Thereby, all cell lines were found
to express PKC-isoenzymes a, d, e and z, and increased basal
degradation rates of PKC-a were only observed in proliferating
and oncogene-altered cells. Moreover, PKC-a was found to be
partly associated with cell–cell junctions in primary RPTE, but
this association diminished or disappeared in E1A-immortalized
or SV40-transformed RPTE respectively (Dong et al, 1993).
In the present study, we analysed the effects of different PKC-
inhibitors on invasion of human RCC in vitro, and in vitro
invasiveness was compared to distinct expression levels and
intracellular distribution patterns of PKC-isoenzymes.
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Cell lines and cell culture conditions
The human RCC cell lines clearCa-5, clearCa-19, clearCa-28 and
clearCa-39 were established from four different human RCCs of
the clear cell type with histologically confirmed diagnosis as
previously described (Gerharz et al, 1993). All cell lines were
maintained in Dulbecco’s modified Eagle medium (DMEM;
Gibco, Karlsruhe, Germany) supplemented with 10% fetal calf
serum (FCS) and antibiotics. Cell lines were incubated at 37°C in
an atmosphere of 5% carbon dioxide.
Growth characteristics
Since growth properties of the tumour cell lines might interfere
with the chick heart invasion assay (CHIA) (see below), prolifera-
tion activities of all four cell lines were determined as previously
described (Engers et al, 1994). Briefly, 15 replicate 25-cm2 flasks
were inoculated with 3 ´ 105 cells each. Cells from three culture
flasks were harvested separately each day for a period of 120 h and
counted by means of a Neubauer chamber. Doubling times were
determined during the exponential growth phase.
PKC-inhibitors
In order to investigate the role of PKC in human RCC invasion,
different PKC inhibitors were used. H7 and staurosporine were
purchased from Sigma (Deisenhofen, Germany). Although not
absolutely PKC-specific, these compounds have been used in the
past in a lot of studies on PKC, but are known also to inhibit some
other protein kinases with a similar potency. CGP 41251 and 
GF 109203X were kindly provided by Dr T Meyer, Ciba-Geigy
(Basel, Switzerland) and Dr J Kirilowsky, Glaxo (Les Ulies,
France), respectively. Although less potent than their progenitor
staurosporine, both compounds exhibit a much higher selectivity for
PKC (Meyer et al, 1989; Toullec et al, 1991). However, not all PKC-
isoenzymes are affected by these inhibitors. Stock solutions of each
PKC-inhibitor were prepared with dimethylsulphoxide (DMSO)
and diluted to final concentrations with standard growth medium.
In order to exclude that possible effects of these inhibitors on
invasion and migration were mimicked by effects on cell prolifer-
ation or toxicity, in initial studies different concentrations of these
compounds were investigated for their effect on cell growth and
cell viability (data not shown). For each compound the respective
maximal non-toxic concentration which did not interfere with cell
proliferation was determined and chosen for subsequent experi-
ments. These concentrations were: 5 nM (CGP 41251), 10 nM
(staurosporine), 500 nM (GF 109203X) and 100 mM (H7).
Chick heart invasion assay
In vitro invasiveness was determined by means of the CHIA as
described (Engers et al, 1999). This assay was chosen because it
closely resembles the complex in vivo mechanism of tumour inva-
sion into a three-dimensional host tissue (Mareel, 1980; Engers et
al, 1999). Heart fragments, dissected from a 9-day-old embryonic
chick, were precultured on a Gyratory shaker for 4 days in order 
to round up and form spheroids. Spheroids with a diameter of 
0.4 mm were selected and brought in contact with tumour cell
aggregates (0.2 mm diameter) on top of a semisolid agar. After
attachment the confronting pairs were individually transferred into
fluid culture medium (either standard growth medium or medium
supplemented with PKC-inhibitors) for further incubation. After
incubation for the respective indicated periods of time, five
confronting pairs each were fixed, followed by embedding in
paraffin and complete serial sectioning. The three-dimensional
extent of invasion was quantified by estimating the volume of host
tissue that had been replaced by the tumour cells according to the
following scale: 0–5%, 6–25%, 26–50%, 51–75% and 76–100%.
PKC-inhibitors were used at final concentrations of 100 mM
(H7), 10 nM (staurosporine), 5 nM (CGP 41251) and 0.5 mM (GF
109203X). DMSO did not affect invasion at the concentrations
used in this study (data not shown).
Protein fractionation and immunoblotting
Subconfluent monolayers were lysed using an ice-cold buffer 
that was 20 mM Tris–HCl (pH 7.4), 2 mM EGTA, 2 mM
disodium–calcium–EDTA, 6 mM mercaptoethanol, 2 mg  ml–1
aprotinin and 2 mg ml–1 leupeptin. Lysates were sonicated on ice
for ten cycles, centrifuged (13 000 rpm, 4°C) and supernatants
were collected as soluble fraction. The remaining pellets were
resuspended in lysis buffer, supplemented with 1% NP-40 and
sonicated for another ten cycles. After centrifugation (13 000 rpm,
4°C) supernatants were collected as particulate fractions. Equal
amounts of protein were separated by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to nitrocellulose membrane. Detection of PKC-a, -bI, -bII, -g, -d,
-e, h(L), -q, -m and -z was performed by means of polyclonal anti-
bodies, generated against isoenzyme-specific peptide sequences of
the C-terminus as described (Marte et al, 1994; Johannes et al,
1995). Two different polyclonal antibodies against PKC-i were
purchased from Santa Cruz Biotechnology (Heidelberg, Germany)
and Transduction Laboratories (Lexington, KY, USA). For detec-
tion a commercially available ECL-detection kit (Boehringer
Mannheim, Mannheim, Germany) was used according to the
manufacturer’s instructions.
In case of PKC-d additional total cell lysates were prepared
from all cell lines and from normal human kidney epithelial cells
using the same buffer, containing 1% NP-40, as mentioned above.
As a positive control the rat rhabdomyosarcoma cell line BA-
HAN-1C (Gabbert et al, 1988) was used.
Immunocytochemistry
Intracellular distribution of PKC-isoenzymes was determined by
means of immunofluorescence microscopy which was essentially
performed as previously described (Engers et al, 1994). Primary
antibodies used were polyclonal isoenzyme-specific antibodies
against PKC-a, -d, -e, or -z from Santa Cruz (Heidelberg,
Germany). Two different polyclonal antibodies against PKC-i
were purchased from Santa Cruz Biotechnology (Heidelberg,
Germany) and Transduction Laboratories (Lexington, KY, USA).
A monoclonal antibody against PKC-m was kindly provided
by Dr FJ Johannes (Stuttgart, Germany) (Johannes et al, 1994).
Secondary antibodies were fluorescein isothiocyanate (FITC)-
labelled anti-rabbit or anti-mouse antibodies, purchased from
Dako (Hamburg, Germany).
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Chromosome 3p deletions are a common characteristic of clear
cell RCCs (Kovacs et al, 1988). In order to determine whether the
observed absence of PKC-d expression on protein and RNA levels
in our RCC cell lines (see below) was caused by a deletion of the
PKC-d gene, which is located on the short arm of chromosome 3,
Southern blot analysis was performed. Total genomic DNA from
tumour cell lines and from normal kidney tissue, which served as
control, was prepared according to standard protocols. Four micro-
grams of either BamHI, EcoRI, XhoI, PstI, or HindIII-digested
DNA were run on a 1% agarose gel and were alkaline blotted
overnight onto a Gene Screen Plus membrane according to the
manufacturer’s instructions (NEN Lifescience, Boston, MA,
USA). Blots were probed with a cloned, full-length 2 kb rat PKC-
d cDNA fragment, kindly provided by Dr FJ Mushinski (Bethesda,
MD, USA), using the Rediprime Kit (Amersham Life Science,
Little Chalfort, UK). Hybridisation was performed overnight in
sodium phosphate-buffered formamide solution (50% formamide,
5 ´ SSC (saline–sodium citrate), 1% SDS, 2 ´ Denhardt’s, 5%
dextran sulphate, 0.2 mg ml–1 salmon sperm DNA) and after
several washing steps exposed to KODAK XAR films overnight.
RESULTS
In vitro invasiveness and effects of different PKC-
inhibitors
In the CHIA, imitating the complex mechanism of tumour cell
invasion into a three-dimensional host tissue, major differences in
in vitro invasiveness became evident among the four human RCC
cell lines (Figure 1A). ClearCa-5 and clearCa-19 were highly inva-
sive, invading the host tissue by 76–100% after 10 days of incuba-
tion. In contrast, clearCa-28 and clearCa-39 exhibited only low
invasive capacities, the maximal extent of invasiveness not
exceeding 5% of the host tissue after 10 days of incubation.
Since differences in cell proliferation might contribute to differ-
ences in in vitro invasiveness after long time of incubation, growth
properties of all four cell lines were determined. Although marked
differences in cell growth were seen among the four cell lines, no
correlation became evident between growth activity and in vitro
invasiveness. Thus, the highly invasive cell line clearCa-19 exhib-
ited a markedly lower proliferation activity (mean doubling time
74.6 h) than the low invasive cell line clearCa-28 (mean doubling
time 34.7 h). These results exclude that the observed differences in
invasion among the different cell lines resulted simply from differ-
ences in proliferation. The mean doubling times for clearCa-5 and
clearCa-39 were 27.5 h and 121.4 h respectively.
In order to investigate the functional role of PKC in human RCC
invasion, the effects of different PKC-inhibitors were investigated.
Whereas in vitro invasiveness of the weakly invasive cell lines
clearCa-28 and clearCa-39 was not affected by either compound
(data not shown), marked anti-invasive effects were observed in
the highly invasive cell lines clearCa-5 and clearCa-19 (Figure
1B). Over a time course of 7 days, H7 exhibited the most
pronounced effects, inhibiting invasion of both clearCa-5 and
clearCa-19 by approximately 70% and 90%, respectively,
compared to non-treated control cells. Similar to H7, both stau-
rosporine and the specific PKC-inhibitor CGP 41251 markedly
inhibited invasion of clearCa-5 and clearCa-19, but the effects
were less pronounced at the concentrations used. In contrast to
CGP 41251, another staurosporine-derived specific PKC-inhibitor,
GF 109203X, inhibited invasion exclusively in clearCa-5 and only
during the first 4 days.
Immunoblotting
To investigate, whether differences in invasion between the four
human RCC cell lines were correlated with differences in PKC-
isoenzyme expression, immunoblot analyses were performed.
Since activation of PKC-isoenzymes results in a redistribution of
the proteins and association with intracellular membranes, proteins
were extracted from both soluble (cytosolic) and particulate
(membrane) fractions. All cell lines expressed PKC-a, -e, -m, -z
and -i (Figure 2A), whereas PKC-bI, -bII -d, -g, -h(L) and -q
proved to be absent as confirmed by RT-PCR and subsequent
isoenzyme-specific oligonucleotide hybridisation (data not
shown). PKC-a was either predominantly or exclusively
expressed in the soluble, PKC-e predominantly in the particulate
fractions of all four RCC cell lines. Except for PKC-m in clearCa-
19 and PKC-z in clearCa-39, PKC-m, -z and -i were not preferen-
tially expressed in any of these fractions. Moreover, no obvious
association was found between in vitro invasiveness and the
expression levels of any PKC-isoenzyme. However, the strongest
expression levels of PKC-e were found in clearCa-5 and clearCa-
28, and thus correlated with a high proliferation activity.
Interestingly, PKC-d, known to be expressed by RPTE cells of
the rat, was absent in all of our RCC cell lines as well as in normal
human kidney epithelial cells, while the rat rhabdomyosarcoma
cell line BA-HAN-1C (Gabbert et al, 1988), used as a positive
control, was positive (Figure 2B). This result cannot be attributed
to species specificity of the antibody, because a polyclonal anti-
body, recognising both human and rat PKC-d, was used.
Intracellular distribution of PKC-isoenzymes
Since isoenzyme-specific subcellular distribution patterns of PKC
are indicative for isoenzyme-specific functions (Goodnight et al,
1995), we investigated by immunofluorescence microscopy
whether differences in invasion between our human RCC cell lines
were associated with distinct intracellular distribution patterns of
individual PKC-isoenzymes (Figure 3).
PKC-a was diffusely expressed in the cytoplasm of all cell lines
and in association with cell membranes, when cell–cell contacts
were established. Interestingly, the strongest association of PKC-a
with cell–cell contacts, indicative for activation of PKC-a
(Goodnight et al, 1995), was observed in cell lines with a highly
invasive potential (clearCa-5 and clearCa-19), while in the low
invasive cell lines membrane-association of PKC-a was either
found to a markedly lower extent (clearCa-28) or was entirely
absent (clearCa-39). Additional expression patterns of PKC-a
such as a dotted staining throughout the cytoplasm and a focal
enhancement in the perinuclear zone, indicating an association
with the endoplasmic reticulum and the Golgi apparatus, respec-
tively (Goodnight et al, 1995), did not correlate with invasive
properties.
Similar to PKC-athe expression pattern of PKC-ecorrelated with
in vitro invasiveness, as localisation at cell membranes, reflecting
activation of the enzyme (Goodnight et al, 1995), was only detected
in the highly invasive cell lines clearCa-5 and clearCa-19. PKC-e
was also expressed in a punctated pattern throughout the cytoplasm
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clearCa-28), and in the nucleus (clearCa-19). For these localisations,
however, no correlation with invasion was found.
Expression patterns of PKC-z and PKC-m were partly hetero-
geneous, cell line- and isoenzyme-specific. An association with in
vitro invasiveness was not observed. In contrast to immuno-
blot analysis, PKC-i was not detectable by immunocytochemistry
in any of the cell lines, although two different antibodies and
different concentrations of the antibodies were used.
In some cases cell membrane localisation of distinct PKC iso-
enzymes was not observed by immunofluorescence microscopy,
although clear signals were seen in the respective particulate frac-
tions by immunoblotting. These results, however, are not neces-
sarily contradictory, because particulate fractions not only harbour
proteins associated with the cell membrane, but also proteins
associated with intracellular membranes such as from the Golgi
apparatus or the endoplasmic reticulum.
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Figure 1 In vitro invasiveness of human RCC cell lines as determined by the CHIA and effects of different PKC-inhibitors. (A) In standard growth medium
clearCa-5 and clearCa-19 almost completely replaced the host tissue by invasion after 10 days of incubation, while clearCa-28 and clearCa-39 exhibited very
low invasive capacities, the maximal extent of invasion not exceeding 5% of the host tissue after the same time of incubation. Results are representative for two
independent experiments, each of which with 5 different spheroids per cell line. Scale bars, 50 mm. (B) Effects of different PKC-inhibitors on invasion of human
RCC cell lines in the CHIA during a time course of 7 days. The extent of invasion is indicated as % of the host tissue which was replaced by tumour cell
invasion. C: control, H7: H7, ST: staurosporine, GF: GF 109203X, CGP: CGP 41251. Results are representative for two independent experiments, each of
which with five different spheroids per cell line, compound and day
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BExpression analysis for PKC-d
Although in rat kidneys PKC-d is known to be expressed by RPTE
cells, from which RCCs of the clear cell type are histogenetically
derived (Dong et al, 1994), PKC-d was absent in all human RCC
cell lines investigated, as shown by immunoblotting and immuno-
fluorescence microscopy. This lack of PKC-d expression was
confirmed by immunoprecipitation/immunoblotting and by RT-
PCR and PKC-d-specific oligonucleotide hybridisation (data not
shown). The PKC-d gene is located on chromosome 3p, but its
exact position is still unknown (Huppi et al, 1994). Since deletions
on chromosome 3p are observed in more than 90% of RCCs of the
clear cell type (Kovacs et al, 1988), we investigated whether the
observed lack of PKC-d expression in our RCC cell lines was due
to a deletion of the PKC-d gene. Southern blot analysis revealed,
however, that all cell lines as well as normal human kidney epithe-
lial cells harboured the PKC-d gene (Figure 2B). These results
indicate that (1) the PKC-d gene is not commonly deleted in
human RCCs of the clear cell type and (2) that in contrast to rat
kidney epithelial cells, human kidney epithelial cells lack PKC-d
expression on the protein and mRNA level.
DISCUSSION
In the present study we characterised four different human RCC
cell lines of the clear cell type for their invasive potential in vitro
and investigated the effects of different PKC-inhibitors on human
RCC invasiveness. At concentrations which did not affect cell
growth, both non-selective and selective PKC-inhibitors exhibited
marked anti-invasive effects in the highly invasive cell lines,
clearCa-5 and clearCa-19, whereas invasion of the weakly inva-
sive cell lines clearCa-28 and clearCa-39 was not affected. These
results suggest an invasion-promoting role of PKC in human RCC
as was also suggested for other tumour types, in which PKC-
inhibitors of other selectivity than GF 109203X and CGP 41251
were used (Schwartz et al, 1993; Mapelli et al, 1994; Hoelting et
al, 1996). Differences in the extent of inhibition of invasion among
the different PKC-inhibitors might be explained by known differ-
ences of the inhibitors in: (1) their specificities for the PKC family,
(2) their specificities for distinct PKC-isoenzymes and (3) by
differences in the potency to inhibit distinct PKC-isoenzymes at
certain subcellular localisations (Meyer et al, 1989; Toullec et al,
1991; Budworth and Gescher, 1995). Thus, H7 is about four times
more effective in inhibiting membrane-bound PKC than cytosolic
PKC, whereas inhibitory effects of CGP 41251 on cytosolic PKC
are about 14 times stronger than on membrane-bound PKC.
Moreover, differences in metabolic degradation during the incuba-
tion period might account for the reduced anti-invasive potencies
of GF 109203X and CGP 41251 after 7 days of incubation,
compared to H7 and staurosporine. Finally, the different PKC-
inhibitors were used in our study at concentrations which did not
affect cell proliferation. Therefore, in case distinct compounds
inhibit proliferation at lower concentrations than invasion, their
anti-invasive effects would have been underestimated.
We next investigated whether differences in invasion between
the four different RCC cell lines were associated with differences
in PKC-isoenzyme expression. By cell fractionation and immuno-
blotting all cell lines were shown to express PKC-isoenzymes a, e,
m, z and i. PKC-a was either predominantly or exclusively located
in the soluble, PKC-e in the particulate fraction, as was similarly
reported for a breast cancer cell line (Disatnik et al, 1994).
However, no preferential localisation of any other PKC-isoenzyme
with one of these fractions was seen. When compared to cell
biological properties, high expression levels of PKC-e were corre-
lated with a high proliferation activity, which is consistent with
studies on fibroblasts, in which overexpression of PKC-e induces
cell growth and oncogenicity (Cacace et al, 1993). Our results
PKC in human renal cell carcinoma invasion 1067




































Figure 2 PKC-isoenzymes in clearCa-5, clearCa-19, clearCa-28 and
clearCa-39. (A) Expression levels of PKC-isoenzymes separated for both
soluble (s) and particulate (p) fractions as determined by immunoblotting.
PKC-bI, -bII, -g, -d, -h(L) and -q were not expressed. (B) Immunoblot (IB) and
Southern blot analysis (SB) for PKC-d in the same human RCC cell lines,
normal human kidney epithelial cells (NKEC) and the rat rhabdomyosarcoma
cell line BA-HAN-1C which served as a positive control. Immunoblots were
performed from total cell lysates. The southern blot shown was performed
using BamHI-digested DNA. Double bands in BA-HAN-1C result from an
additional BamHI restriction site in rat PKC-d when compared to human
PKC-d. Results are representative for three independent experimentstherefore suggest that PKC-e might also be involved in the regula-
tion of proliferation in human RCCs.
In contrast to proliferation, no strict correlation was observed
between the expression levels of distinct PKC-isoenzymes, as
determined by immunoblotting, and in vitro invasiveness. This
lack of correlation, however, does not necessarily rule out a role of
PKC in RCC invasion, since not merely the expression levels, but
also the subcellular distribution of PKC-isoenzymes is thought to
be of major importance for their specific functional activities
(Buchner et al, 1995; Goodnight et al, 1995; Kiley and Parker,
1995; Jaken et al, 1997). In our RCC cell lines the subcellular
expression patterns of PKC-a, -e, -m and -z, as determined by
immunofluorescence, proved to be partly isoenzyme- and cell
line-specific. Nevertheless, a strong correlation between the
subcellular expression patterns of both PKC-a and PKC-e and in
vitro invasiveness of human RCCs became evident. Thus, associa-
tion of PKC-e with the cell membrane and localisation with
cell–cell contacts was exclusively restricted to the highly invasive
cell lines and was completely absent in the low invasive cell lines.
Similarly, the strongest association of PKC-a with cell–cell
contacts was observed in cell lines with a high invasive potential,
while in the low invasive cell lines membrane-association of PKC-
a was either found to a markedly lower extent or was not
detectable at all. Translocation of PKC-a and PKC-e to the cell
membrane has been shown to occur upon activation of the
enzymes (Goodnight et al, 1995). Therefore, our results suggest a
particular activation of PKC-a and PKC-e in highly invasive RCC
cell lines and hence a possible role of these PKC-isoenzymes in
RCC invasiveness. These results are in line with the observation,
that overexpression of PKC-a or PKC-e induces a more aggres-
sive or an oncogenic phenotype respectively (Cacace et al, 1993;
Ways et al, 1995).
The observed expression pattern of PKC-isoenzymes (PKC-a, -
e, -m, -z and -i) in human RCC cell lines differs from that of other
tumour types (Selbie et al, 1993; Disatnik et al, 1994; Mapelli et
al, 1994) and therefore suggests tumour-specific rather than
unique functions of PKC and PKC-isoenzymes. However, the
presence of PKC-a, -e and -z in RCCs is in line with studies on
renal proximal tubule epithelial cells (RPTE) (Dong et al, 1994),
from which RCCs of the clear cell type are histogenetically
derived. PKC-m and -i are also known to be expressed by normal
kidney tissue, though their expression has not yet been attributed
to distinct cellular compartments of the kidney (Selbie et al, 1993;
Johannes et al, 1994). Interestingly, PKC-d, known to be
expressed by both normal and transformed RPTE of the rat, was
absent in all four RCC cell lines as well as in normal human
kidney epithelial cells on protein and RNA levels. The PKC-d
gene is located on chromosome 3p, but its exact localisation is still
unknown (Huppi et al, 1994). Since chromosome 3p deletions are
found in almost all human RCCs of the clear cell type (Kovacs et
al, 1988), it was tempting to speculate, whether the observed lack
of PKC-d expression in our tumour cell lines was due to a common
deletion of the PKC-d gene. However, by Southern blot analysis
all cell lines as well as normal human kidney epithelial cells were
shown to harbour the PKC-d gene. These results indicate that: (1)
the PKC-d gene is not commonly deleted in human RCCs of the
clear cell type, (2) that in contrast to rat kidney epithelial cells,
human kidney epithelial cells lack PKC-d expression on the
protein and mRNA level, and hence that organ-specific expression
patterns of PKC-isoenzymes are not necessarily conserved during
evolution.
In conclusion, our results suggest a role for PKC in the regula-
tion of human RCC invasiveness. The fact that distinct expression
patterns of PKC-a and/or -e were correlated with invasion and/or
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Figure 3 Differential subcellular expression patterns of PKC-isoenzymes in human RCC cell lines as determined by immunofluorescence microscopy. Using a
FITC-labelled secondary antibody, isoenzyme-specific localisations are indicated by a green fluorescence signal. Results are representative for three
independent experiments. All pictures were taken by the same magnification. Scale bar, 25 mmproliferation might argue for a particular role of both PKC-
isoenzymes in these biological properties. The elucidation of these
roles will be subject of further studies.
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